Michael GERG,Dieter HEINDL,Gerhard NIEDERFELLNER,Wolfgang SCHAEFER,Michael SCHRAEML,Michael TACKE
申请号：
US16704781
公开号：
US20200207874A1
申请日:
2019.12.05
申请国别(地区):
US
年份:
2020
代理人:
摘要：
Herein is reported a polypeptide-polynucleotide-complex as therapeutic agent and its use as tool for the targeted delivery of an effector moiety. The polynucleotide part of the complex is essentially resistant to proteolytic and enzymatic degradation in vivo. Additionally the polypeptide part specifically binds to a compound or structure such as a tissue or organ, a process or a disease. Thus, one aspect as reported herein is a polypeptide-polynucleotide-complex comprising a) a polypeptide specifically binding to a target and conjugated to a first member of a binding pair, b) a polynucleotide linker conjugated at its first terminus to the second member of the binding pair, and c) an effector moiety conjugated to a polynucleotide that is complementary to at least a part of the polynucleotide linker.
